Uproleselan

Product Description

GlycoMimeticsÕ investigational, first-in-class, targeted antagonist of E-selectin, to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated AML who are suitable for intensive chemotherapy. Discovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class, targeted antagonist of E-selectin. Uproleselan (yooÕ pro leÕ sel an), currently in a comprehensive Phase 3 development program in AML, has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and the Chinese Health authority for the treatment of adult patients with AML who have relapsed or refractory disease. Uproleselan is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance. (Sourced from: https://ir.glycomimetics.com/news-releases/news-release-details/nci-sponsored-trial-uproleselan-older-newly-diagnosed-aml)

Mechanisms of Action: SELE Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: Breakthrough Therapy - Acute Leukemia|Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlycoMimetics
Company Location: ROCKVILLE MD 20850
Company CEO: Harout Semerjian
Additonal Commercial Interests: Apollomics